Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab for GVHD Prophylaxis in RIC Allo-Transplant
NCT00781781Phase 2Terminated
- Sponsor
- CABYC
- Start
- Jul 2008
- Primary completion
- Aug 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of alemtuzumab in graft-versus-host disease (GVHD) (2 arms), sponsored by CABYC. Primary endpoints: Incidence and severity of acute Graft Versus Host Disease at 3 years and Incidence and severity of chronic Graft Versus Host Disease at 3 years. Started Jul 2008; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00781781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781781.